Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) EBIT Margin (2021 - 2025)

Historic EBIT Margin for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to 3827.4%.

  • Aligos Therapeutics' EBIT Margin fell 22169200.0% to 3827.4% in Q3 2025 from the same period last year, while for Sep 2025 it was 3306.67%, marking a year-over-year decrease of 14201900.0%. This contributed to the annual value of 2468.96% for FY2024, which is 15252100.0% down from last year.
  • As of Q3 2025, Aligos Therapeutics' EBIT Margin stood at 3827.4%, which was down 22169200.0% from 1924.04% recorded in Q2 2025.
  • Aligos Therapeutics' EBIT Margin's 5-year high stood at 445.76% during Q2 2023, with a 5-year trough of 10340.05% in Q4 2021.
  • In the last 5 years, Aligos Therapeutics' EBIT Margin had a median value of 1913.59% in 2021 and averaged 2455.34%.
  • As far as peak fluctuations go, Aligos Therapeutics' EBIT Margin skyrocketed by 96987800bps in 2022, and later crashed by -30108000bps in 2025.
  • Quarter analysis of 5 years shows Aligos Therapeutics' EBIT Margin stood at 10340.05% in 2021, then soared by 94bps to 641.28% in 2022, then plummeted by -102bps to 1294.03% in 2023, then crashed by -162bps to 3393.23% in 2024, then decreased by -13bps to 3827.4% in 2025.
  • Its EBIT Margin was 3827.4% in Q3 2025, compared to 1924.04% in Q2 2025 and 6187.46% in Q1 2025.